Open-label PhaseII trial evaluating activity&safety of JDQ443 single-agent as 1st-line treatment for locally advanced or metastatic KRAS G12C-mutant NSLC

Studiedetails

Type carcinoma: NSCLC met mutatie
Stadium:
Mutatie: KRAS G12C, STK11
Lijn: 1e
Site: Erasmus MC & Amphia
Contactgegevens:

long.oncologie@erasmusmc.nl
researchlongoncologie@amphia.nl
Website:

 Inclusiecriteria

– Only histology tissue
– No previous systemic treatment for metastatic disease. Prior (neo)adjuvant treatment with chemotherapy and/or immunotherapy, or prior radiotherapy administered sequentially or concomitantly with chemotherapy and/or immunotherapy for localized or locally advanced disease are accepted if the time between therapy completion and enrollment is > 12 months
– ECOG performance status ≤ 1

 Exclusiecriteria

Meer studies

Een overzicht van alle lopende studies binnen het longkankernetwerk. Filter op type mutatie:

KontRASt-06

An open-label Phase II trial evaluating the activity and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C-mutant non-small cell lung cancer (NSCLC) with a PD-L1 expression <1% or a PD-L1 expression ≥1% and an STK11 co-mutation